

The Role of Mitochondria in Cartilage Degenerative Disorders

Yuriy Nalapko^{1*}, Jonathan R. T. Lakey²⁻⁴, Orn Adalsteinsson⁵, Dmytro Klokol⁶, Thomas Skutella⁷, Shing Yi Pan⁸, Augusta Wellington⁹, Michelle B. F. Wong¹, Mike K. S. Chan¹ and Desiree Cox⁴

¹European Wellness International, Klosterstrasse 205a, Edenkoben, 67480, Germany.

²Department of Neurobiology, University of California Irvine, Irvine, CA, 92697, USA.

³Department of Surgery and Biomedical Engineering, University of California Irvine, Orange, CA, 92868, USA.

⁴BioPep, 4621 Technology Drive, Golden, CO, 80403, USA.

⁵Intl Cancer Alliance, 23 Fern Hill Rd, Kennett Square, PA 19348, USA.

⁶European Wellness Academie (Asia Pacific), 67-68 Block K, Alamesra Plaza Utama, Jalan Sulaman, Kota Kinabalu, 88450, Malaysia.

⁷Group for Regeneration and Reprogramming, Medical Faculty, Institute for Anatomy and Cell Biology, Heidelberg University, Heidelberg, 69120, Germany.

⁸Baden R&D Research, Klosterstrasse 205a, Edenkoben, 67480, Germany.

⁹Institute for Psychoanalytic Training and Research, 15 High Vista Drive, Nassau, Bahamas.

Citation: Yuriy Nalapko, Jonathan R. T. Lakey, Orn Adalsteinsson, et al. The Role of Mitochondria in Cartilage Degenerative Disorders. Int J Biomed Res Prac. 2022; 2(1); 1-6.

*Correspondence:

Dr. Yuriy Nalapko, European Wellness International, Klosterstrasse 205a, Edenkoben, 67480, Germany.

Received: 08 Jun 2022; **Accepted:** 04 Jul 2022; **Published:** 09 Jul 2022

ABSTRACT

Mitochondria are major organelles that produce energy for cellular metabolism and are vital to proper cell functioning. Metabolic dysregulation is a critical contributing factor to the initiation and development of degenerative and autoimmune diseases, thus is present in cartilage disorders such as osteoarthritis and rheumatoid arthritis. Mitochondrial dysfunction in cartilage diseases is especially interesting because it may present a promising therapeutic and anti-ageing target. By understanding the mechanism of mitochondrial dysfunction, we can aim to upregulate the role of mitochondria in treating cartilage diseases. In this review, we look at the role of mitochondrial dysfunction in degenerative cartilage diseases and mitochondria as tools in the treatment of osteoarthritis and rheumatoid arthritis.

Keywords

Regenerative medicine, Cartilage diseases, Joint degeneration, Mitochondria, Mitochondrial dysfunction.

Introduction to Mitochondria Biology

The mitochondrion is an intracellular organelle in most eukaryotic cells that carries out many essential cellular functions. Mitochondria are the main location for adenosine triphosphate (ATP) production in cells and are thus known as the “power plant” of the cell. The

inner mitochondrial membrane is presented by cristae, which provide a high surface area for housing the protein complexes of the electron transport chain and ATPase, thereby controlling cellular metabolism. Several substances (e.g., pyruvate, glutamine, and fatty acids) enter the tricarboxylic acid cycle in the mitochondrial matrix to generate the electron carriers and transfer their electrons to the electron transport chain embedded in the inner mitochondrial membrane, in a process known as oxidative phosphorylation. This oxidative phosphorylation pathway generates about 90% of cellular ATP in mitochondria [1].

In addition to their primary function, mitochondria play several additional crucial roles. Mitochondria operate as a central hub of both catabolic and anabolic reactions. Acetyl coenzyme A (acetyl-CoA) is condensed with oxaloacetate by citrate synthase in the mitochondria, generating citrate and free CoA. Mitochondria are also involved in heme biosynthesis, indispensable for cellular respiration, energy metabolism, and cell survival. Mitochondria alter their bioenergetic and biosynthetic functions to meet the cell's metabolic demands and continuously communicate their functionality to the rest of the cell [2]. ATP production requires a continuous flow of electrons through oxidative phosphorylation. As such, mitochondria are the primary source of reactive oxygen species (ROS), including superoxide and H₂O₂. ROS reflect the degree of cellular oxidative stress, causing severe damage to macromolecules when overproduced [3].

Each mitochondrion has its genome. Many of the mitochondrial DNA (mtDNA) genes encode proteins, while the others are involved in the proteins translation. Such proteins encoded by mtDNA are vital for healthy cellular function. However, the mitochondrial genome is susceptible to oxidative damage. As a result, such injury to the mitochondrial genome has been linked to cell apoptosis, tissue degeneration and other age-related disorders [4].

Conversely, ageing and degenerative diseases are associated with an elevated oxidant state that may cause mitochondrial damage. Several pathologies in this category share the common features of mitochondrial Ca²⁺, ATP, or ROS metabolism disturbances. Some of these disorders include chronic autoimmune diseases (e.g., rheumatoid arthritis) and articular cartilage degenerative diseases (e.g., osteoarthritis). Thus, therapeutic interventions with mitochondria could be effective tool for cartilage diseases [5,6].

In essence, mitochondria are important targets for the treatment strategies. They represent an attractive target for mitochondrial therapy and for treating a range of age-related degenerative diseases.

Mitochondria as a Therapeutic Target

The modern approach to restore the mitochondria's structure and functions include small molecule drugs, biologically active mitochondrial proteins and peptides, and stem cell therapy. The mitochondrial function relies on the electron transport chain to build polarization across the inner membrane, which in turn drives

energy production [7]. Mitochondrial dysfunction triggers the cell senescence and death-signalling cascade and results in ageing, organ failure and disease. The functioning of the mitochondrial permeability transition pore regulates the maintenance of the potential of the mitochondrial membrane [8]. Its abnormal opening induces the collapse of the mitochondrial membrane potential and the release of cytochrome c, an apoptotic factor, into the cytosol. A widely used strategy for targeting mitochondria demonstrates the advantage of this remarkable biophysical membrane property: the ability of cationic molecules to attract to and accumulate preferentially within the negatively charged mitochondrial matrix.

Another strategy is based on the affinity of an agent to mitochondrial membrane components. Small molecule drugs or biologically active substances can act on mitochondria through various pathways [9]. These mechanisms include electron transport chain inhibition, uncoupling of oxidative phosphorylation, mitochondrial Ca²⁺ modulation, and oxidative stress control via decrease or increase of mitochondrial ROS accumulation. Other strategies for drug-induced perturbation of mitochondrial biochemistry include the inhibition of peroxidation of the mitochondria-specific phospholipid cardiolipin and targeting other specific mitochondrial proteins [10].

Mitochondrial biochemistry can be damaged by mtDNA binding/oxidation, inhibition of mtDNA synthesis, or modulation of mitochondrial fission/fusion. Recently, compounds that modulate mitochondrial fission/fusion have been proposed as valuable alternatives in treating degenerative diseases [11].

An emerging approach to the selective delivery of bioactive molecules into mitochondria involves using a carrier of short peptide sequences with specific chemical properties. For instance, Horton et al. reported mitochondria-penetrating peptides with alternating cationic and hydrophobic residues [12]. Other types are based on an oligomeric carbohydrate scaffold [13]. The vesicle-based transporter system is another class of mitochondrial delivery vectors that is suitable for importing large or impermeable molecules [13]. The active substance is encapsulated in a liposome and internalized by the cell, and subsequently fuses with the outer mitochondrial membrane.

Another technology to regulate the mitochondrial structure is using of the peptide- and amino acid-based mitochondria-targeted agents. Glutathione plays an important role in protecting cells against oxidants. Two-glutathione molecules react together to form glutathione disulfide after donating an electron to unstable molecules such as ROS. Increasing mitochondrial glutathione can be an effective strategy to prevent mitochondrial oxidative stress. Sheu et al. used a similar approach and prepared choline esters of glutathione and its analogue N-acetyl-L-cysteine for targeting mitochondria [14].

Mitochondrial function and properties depend on the cell type. Thus, a better understanding of mitochondrial properties is of interest to researchers and clinicians, particularly, stem cells for use in anti-

ageing and bioregenerative medicine. Since stem cells rely mostly on a glycolytic metabolism rather than oxidative phosphorylation for energy production, they are thought to be almost independent of mitochondrial function [15]. Importantly, recent studies have shown that proper mitochondrial function in stem cells is essential to support their self-renewal and differentiation abilities.

In summary, mitochondria-targeting agents based on peptides possess advantages over other mitochondria-acting agents, including biological compatibility and synthesis. Peptides that penetrate the mitochondrial membrane must be rationally designed to have optimum positive charge and hydrophobicity [12]. It could be achieved by incorporating lipophilic cations or positively charged arginine into the peptide design [12]. In this way, mitochondria-acting peptides are one of the promising directions in degenerative disease therapeutics.

Mitochondria as the Tool of the Therapy

Despite mtDNA encoding about 60 proteins, mitochondria need around 2000 proteins for their normal function. Most such proteins are synthesized in the cytoplasm through ribosomes encoded in the nucleus. This independence makes them relatively independent from the mitochondrial genome [16]. The nuclear/mitochondrial gene interactions are vital for the translation of proteins and mitochondria respiration. Cells tend to dispose of their mitochondria after exposure to stress conditions or when keeping them becomes harmful since mitochondria can produce large quantities of ROS [17].

Mitochondrial Transfer

Extracellular vesicles (EVs) transport intracellular cargo to other cells, including transporting different substances to mitochondria. EVs are structures surrounded by a lipid bilayer membrane [18] capable of transporting proteins, lipids, carbohydrates, metabolites, small RNAs, and mtDNA. Exosomes are EVs with the greatest size (30-100 nm diameter) [19]. Exosomes could transport mRNA and microRNA to the recipient cells and, therefore, control activities in such cells [20]. Guescini et al. also observed the delivery of mtDNA by exosomes [21].

The mitochondria's small size and capacity to change shape and length allow them to be transported by subcellular transport mechanisms such as tunnelling nanotubes (TNTs) and EVs. Rustom et al. [22] described TNTs as structures that enable cell-to-cell interaction. Since then, many groups have studied the cells producing TNTs and receiving mitochondria and other intracellular cargo [22]. These studies prove that TNTs are involved in mitochondrial transport between cells, repairing cell damage, and activating cell metabolic reprogramming.

The directionality of the transport of mitochondria through the TNTs is not fully understood. Therefore, it is important to define what factors promote the donation of material and their effects on the recipient cells. Assays to optimize transfers involving chemical compounds and physical methods have been performed. In 2013, Chang and colleagues conjugated isolated mitochondria

with penetrating peptides to foster their internalization [23]. They used Pep-1, a cell-penetrating peptide, which was developed to make pores in the membrane to deliver the molecules (e.g., oligonucleotides) into the cell. The scientists adapted Pep-1 to conjugate it with isolated mitochondria of human osteosarcoma 143B cells. The combination of Pep-1 and the isolated mitochondria promoted their internalization by fibroblasts involved in a mitochondrial disease myoclonic epilepsy model with ragged red fiber syndrome. As a result, the Pep-1-mediated transfer was more successful in facilitating the internalization of mitochondria than mitochondria alone [23].

The process of mitochondrial transfer allows the re-use of the subcellular organelles of the damaged cells in other cells; this phenomenon is called transmitophagy [24]. The reason for transmitophagy is currently unknown. Understanding the natural transfer of mitochondria by microvesicles and transmitophagy will allow us to find new therapeutic options, which could mediate the recovery of cellular homeostasis and function in degenerative diseases.

Mitochondrial organ and tissue specificity should be considered in the donor mitochondria selection. Mitochondria have different shapes, sizes, energy production potential, and metabolic processes among cell types and stages of differentiation. During cell proliferation, the mitochondria segregate and fuse with other mitochondria [25]. Mitochondria isolated in a specific state, such as proliferation, have a more potent influence on recipient cellular mitochondria networks and are prone to fuse with endogenous mitochondria. Most transfer procedure studies were performed using mitochondria from differentiated cells such as fibroblasts, liver cells and mesenchymal stem cells (MSCs) [26]. Testing these cells at their different states will be essential to understanding how exogenous mitochondria interact with the endogenous organelles, how the cell's phenotype changes after the transfer, and whether metabolic reprogramming is possible.

Most work in mitochondrial delivery between cells involves rescuing damaged cells from healthy ones, such as human MSCs [25]. Some studies have linked such transfer processes to the enhanced immune response of MSCs to macrophages, which is just one example of this mechanism's diverse effects on cells involved in the transfer. MSCs are the optimal cells to transfer mitochondria in bone and cartilage diseases [27], autoimmunity, cancer, and excessive proinflammatory events in sepsis or viral infections [28].

Artificial Mitochondrial Transfer

Considering the symbiotic nature of mitochondria and the cell's capacity to transfer mitochondria to damaged neighbours, many researchers have developed procedures for artificial mitochondrial transfer from one cell to another. The techniques range from simple cocultivation of isolated mitochondria and recipient cells to physical approaches to induce integration. For example, through cocultivation, Clark and Shay completed the first formal mitochondrial transfer from one xenogeneic cell to another in 1982

[29]. Since then, this rapidly growing field has developed new methods of artificial mitochondria transfer to observe its effects on recipient cell types and opens new therapeutic horizons.

In 1988, King and Attardi developed the first artificial mitochondria transfer technique using invasive instruments by injecting exogenous mitochondria isolated from chloramphenicol resistant cells into sensitive human cells [30]. Their work demonstrated that the injection of just one mitochondrion could quickly (in 6 to 10 weeks) repopulate a cell depleted of its endogenous mitochondria [24].

Understanding how artificial mitochondrial transport may induce heteroplasmy in cells carrying mitochondria mutations and encourage the clearance of unhealthy mitochondria copies to support mitochondria quality control by mitophagy may reveal new therapeutic possibilities. Artificial mitochondrial transport could potentially repair endogenous and damaged mitochondria by introducing healthy copies to recipient cells [31]. Artificial mitochondrial transport has shown promising results in healing damaged or stressed cells in vitro and in vivo. Clarification of their mechanisms of action within the cell will allow us to explore and mix artificial mitochondrial transport with other techniques to repair dysfunctional chondrocyte mitochondria.

Mitochondrial Fusion

In 2007, Yoon et al. observed that mitochondria from different species have the ability to fuse with polyethylene glycol [32]. They labelled human and mice mitochondria differently and observed a mix of the two types of mitochondria 45 min after adding the polyethylene glycol and the fusion of mitochondria into hybrids at 4 hours. The fusion of human and animal mitochondria appeared to occur due to the nucleotide similarity between the proteins responsible for this process.

In 2012, Elliott et al. co-incubated mitochondria isolated from immortalized breast epithelial cells with their malignant counterparts. They observed decreased proliferative potential and a higher sensitivity to chemotherapeutic drugs. Remarkably, they also observed that only isolated mitochondria from the immortalized breast epithelial cells, but not the original epithelial cells, could enter the breast cancer cells [33].

Stem Cell Mitochondria

Cells and mitochondria transform during the process of differentiation. It has been suggested that stem cell mitochondria are dormant and immature since they are small and favour anaerobic metabolism. However, through differentiation and loss of their pluripotency, mitochondria proliferate and the quantity of DNA, the generation of ATP synthase, and the rate of respiration increase [34].

MSCs use mitochondria because they are independent of receptors or coupled proteins to induce their effects. In contrast, mtRNAs, cytokines, and other cell components require the activation of specific signal pathways to induce a response of cell proliferation, growth etc. Once inside the cell, exogenous mitochondria begin

to fuse with other mitochondria. These mechanisms make the transport of mitochondria through TNTs or vesicles important to their protection and ensure their integrity and stability [35]. Mitochondrion to mitochondrion DNA transfer is one of the fundamental biological processes that could restore its important functions. The pioneering studies of the xenogeneic cell transfer of mitochondria open new horizons for stem cell medicine.

Mitochondrial Dysfunction in Cartilage Diseases

Cartilage diseases represent one of the most common clinical conditions that cause age-related disability and affect patients' quality of life. Most diseases involving cartilage lead to dramatic degenerative changes in the chondrocyte mitochondria, which can govern disease progression.

Osteoarthritis is a chronic degenerative age-related disease that causes progressive articular cartilage degeneration. Rheumatoid arthritis is a chronic inflammatory and autoimmune disorder caused by a complex interplay of different immune and non-immune cell types. Both osteoarthritis and rheumatoid arthritis result in severe cartilage cell damage that affects multiple joints in the body [36].

Metabolic dysregulation is a critical contributing factor to the initiation and development of autoimmunity disease. Many recent studies have focused on the metabolic processes in inflammatory diseases [37]. Mitochondrial dysfunction is well documented in cartilage diseases, including osteoarthritis and rheumatoid arthritis [38] and has been observed in other diseases [39,40]. Since mitochondria contribute to intra- and inter-cellular signalling through the actions of proteins, DNA, lipids, metabolites, and ROS, mitochondrial components are capable of directly activating the immune system.

Mitochondrial Dysfunction in Osteoarthritis

Mitochondrial dysfunction plays a central role in initiating post-traumatic osteoarthritis [38]. Evidence from ex vivo chondral injury models suggests that in cartilage, as in other tissues, mitochondria may act as intracellular mechanotransducers via strain-activated release of ROS [41]. Chondrocyte compression distorts the mitochondrial network, and chondrocyte cytoskeleton dissolution prevents elevated ROS and cell death in injured cartilage. Increased intracellular calcium leads to mitochondrial depolarization, activation of the caspase cascade and chondrocyte apoptosis. Mitochondrial respiratory dysfunction is identified in the acute phase (within 2 hours) after cartilage impact injury [42].

Several in vivo models have assessed mitochondrial function in the sub-acute to early chronic stages after cartilage insult. In animals, chondrocyte respiratory function stays impaired for four weeks after surgical destabilization of the medial meniscus in rabbits [43]. Similarly, in a mouse destabilization of the medial meniscus model, mitochondrial superoxide overproduction occurred in knee cartilage for two weeks postoperatively [44]. Chondrocytes isolated from superoxide dismutase-2 deficient cartilage displayed mitochondrial depolarization, decreased mitochondrial respiratory function, and swollen mitochondria with disrupted cristae structure.

Osteoarthritis is also associated with the age-related decreased numbers of mitochondria and deficiencies in the metabolic biosensors adenosine monophosphate-activated protein kinase and sirtuin-1, which regulate mitochondrial biogenesis [45]. In addition, mitochondria-associated disease pathways are linked to chronic stages of the disease, including decreased synthesis of collagen and proteoglycans and pathologic calcification of cartilage. Furthermore, mutations of mtDNA affecting mitochondrial function are associated with an increased incidence of knee osteoarthritis [46].

Mitochondrial Dysfunction in Rheumatoid Arthritis

Mitochondrial dysfunction also plays a role in rheumatoid arthritis, as dysregulation of immune signalling pathways causes local inflammation in the synovial joint and systemic complications such as an increased risk of cardiovascular diseases. Mitochondrial products have systemic and local functions and additionally are involved in the pathogenesis of rheumatoid arthritis by promoting synovitis via mtDNA in joints [47]. Rheumatoid factor, anti-citrullinated protein antibodies and other autoantibodies are found in many patients with rheumatoid arthritis and are associated with more severe disease [48].

Due to their multiple effects on the cell, mitochondria contribute to disease pathogenesis via metabolic actions and directly affect signalling pathways. The functions of mitochondria in different cell types in rheumatoid arthritis are well known [37]. Mitochondria facilitate immune cell activation and the production of inflammatory mediators, which have mostly been studied in T cells, macrophages, and fibroblasts. Additionally, there is evidence for mitochondrial regulation of endothelial cells, osteoclasts, neutrophils and chondrocytes in arthritis [49].

Mitochondria also have a well-established role in the process of apoptosis. Apoptosis is important for the control of synovial hyperplasia in rheumatoid arthritis, as both extrinsic and intrinsic processes can trigger it. It occurs intrinsically in mitochondria due to oxidative stress, whereas extrinsic routes are inactive in the fibroblast-like synoviocytes of patients with rheumatoid arthritis.

Mitochondrial therapy, especially tissue-specific mitochondrial-based therapy, is becoming an encouraging approach to regenerative medicine. A recently published review demonstrated the growing interest in stem cell-based bioregenerative therapy conducting the regeneration of new chondrocytes [50]. Nalapko et al. (2022) state that multiple preclinical and clinical trials proved that MSCs and chondrocyte stem cell-based agents are potentially useful regenerative technologies for patients with osteoarthritis [50].

Conclusion

The link between the age-related mitochondrial dysfunction and inflammation/tissue damage in skeletal joint pathologies is emerging in cartilage diseases such as osteoarthritis and rheumatoid arthritis. Increasing evidence suggests that this dysfunction occurs early and causally in disease pathogenesis as the accumulation of mitochondrial damage resulting from compromised quality

control pathways leads to the development of cartilage damage. By understanding the mechanism of mitochondrial dysfunction, we can aim to upregulate the role of mitochondria in treating cartilage diseases, and new therapeutic anti-ageing paradigms can be developed to restore cartilage integrity.

Acknowledgements

The authors would like to thank Melissa Waine for her comments and the literature edition of the manuscript.

References

1. Anderson AJ, Jackson TD, Stroud DA, et al. Mitochondria hubs for regulating cellular. *Biochemistry emerging concepts and networks*. *Open Biol*. 2019; 9: 190126.
2. Gordaliza Alaguero I, Cantó C, Zorzano A. Metabolic implications of organelle-mitochondria communication. *EMBO Rep*. 2019; 20: e47928.
3. Giorgi C, Marchi S, Simoes ICM, et al. Mitochondria and Reactive Oxygen Species in Aging and Age Related Diseases. *Int Rev Cell Mol Biol*. 2018; 340: 209-344.
4. Allkanjari K, Baldock RA. Beyond base excision, repair an evolving picture of mitochondrial DNA repair. *Biosci Rep*. 2021; 41: BSR20211320.
5. Huang ML, Chiang S, Kalinowski DS, et al. The Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases Cross Talk between Antioxidant Defense Autophagy and Apoptosis. *Oxid Med Cell Longev*. 2019; 2019: 6392763.
6. Schneider AM, Özsoy M, Zimmermann FA, et al. Age Related Deterioration of Mitochondrial Function in the Intestine. *Oxid Med Cell Longev*. 2020; 2020: 4898217.
7. Early JO, Fagan LE, Curtis AM, et al. Mitochondria in Injury Inflammation and Disease of Articular Skeletal Joints. *Front Immunol*. 2021; 12: 695257.
8. De Gaetano A, Solodka K, Zanini G, et al. Molecular Mechanisms of mtDNA Mediated Inflammation. *Cells*. 2021; 10: 2898.
9. Valero T. Mitochondrial biogenesis pharmacological approaches. *Curr Pharm Des*. 2014; 20: 5507-5509.
10. Kagan VE, Bayir HA, Belikova NA, et al. Cytochrome c/ cardiolipin relations in mitochondria a kiss of death. *Free Radic Biol Med*. 2009; 46: 1439-1453.
11. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases aging and cancer a dawn for evolutionary medicine. *Annu Rev Genet*. 2005; 39: 359-407.
12. Horton KL, Stewart KM, Fonseca SB, et al. Mitochondria penetrating peptides. *Chem Biol*. 2008; 15: 375-382.
13. Yousif LF, Stewart KM, Kelley SO. Targeting mitochondria with organelle specific compounds strategies and applications. *Chembiochem*. 2009; 10: 1939-1950.
14. Sheu SS, Nauduri D, Anders MW. Targeting antioxidants to mitochondria a new therapeutic direction. *Biochim Biophys Acta*. 2006; 1762: 256-265.
15. Stimpfel M, Hämäläinen RH, May-Panloup P. Mitochondria More than Just Power Plants in Stem Cells. *Stem Cells Int*. 2017; 2017: 1826746.

16. Mokranjac D, Neupert W. Protein import into mitochondria. *Biochem Soc Trans.* 2005; 33: 1019-1023.
17. Rossmann MP, Dubois SM, Agarwal S, et al. Mitochondrial function in development and disease. *Dis Model Mech.* 2021; 14: dmm048912.
18. Pitt JM, Kroemer G, Zitvogel L. Extracellular vesicles masters of intercellular communication and potential clinical interventions. *J Clin Invest.* 2016; 126: 1139-1143.
19. Raposo G, Stoorvogel W. Extracellular vesicles exosomes microvesicles and friends. *J Cell Biol.* 2013; 200: 373-383.
20. Schwarzenbach H, Gahan PB. MicroRNA Shuttle from Cell To Cell by Exosomes and Its Impact in Cancer. *Noncoding RNA.* 2019; 5: 28.
21. Guescini M, Genedani S, Stocchi V, et al. Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. *J Neural Transm.* 2010; 117: 1-4.
22. Rustom A, Saffrich R, Markovic I, et al. Nanotubular highways for intercellular organelle transport. *Science.* 2004; 303: 1007-1010.
23. Chang JC, Liu KH, Li YC, et al. Functional recovery of human cells harbouring the mitochondrial DNA mutation MERRF A8344G via peptide mediated mitochondrial delivery. *Neurosignals.* 2013; 21: 160-173.
24. Caicedo A, Aponte PM, Cabrera F, et al. Artificial Mitochondria Transfer Current Challenges Advances and Future Applications. *Stem Cells Int.* 2017; 2017: 7610414.
25. Mishra VK, Shih HH, Parveen F, et al. Identifying the Therapeutic Significance of Mesenchymal Stem Cells. *Cells.* 2020; 9: 1145.
26. Katrangi E, D'Souza G, Boddapati SV, et al. Xenogenic transfer of isolated murine mitochondria into human rho0 cells can improve respiratory function. *Rejuvenation Res.* 2007; 10: 561-570.
27. Kangari P, Talaei Khozani T, Razeghian Jahromi I, et al. Mesenchymal stem cells amazing remedies for bone and cartilage defects. *Stem Cell Res Ther.* 2020; 11: 492.
28. Piekarska K, Urban Wójciuk Z, Kurkowiak M, et al. Mesenchymal stem cells transfer mitochondria to allogeneic Tregs in an HLA-dependent manner improving their immunosuppressive activity. *Nat Commun.* 2022; 13: 856.
29. Clark MA, Shay JW. Mitochondrial transformation of mammalian cells. *Nature.* 1982; 295: 605-607.
30. King MP, Attardi G. Injection of mitochondria into human cells leads to a rapid replacement of the endogenous mitochondrial DNA. *Cell.* 1988; 52: 811-819.
31. Shanmughapriya S, Langford D, Natarajaseenivasan K. Inter and Intracellular mitochondrial trafficking in health and disease. *Ageing Res Rev.* 2020; 62: 101128.
32. Yoon YG, Haug CL, Koob MD. Interspecies mitochondrial fusion between mouse and human mitochondria is rapid and efficient. *Mitochondrion.* 2007; 7: 223-229.
33. Elliott RL, Jiang XP, Head JF. Mitochondria organelle transplantation introduction of normal epithelial mitochondria into human cancer cells inhibits proliferation and increases drug sensitivity. *Breast Cancer Res Treat.* 2012; 136: 347-354.
34. Zhang H, Menzies KJ, Auwerx J. The role of mitochondria in stem cell fate and aging. *Development.* 2018; 145: dev143420.
35. Chen CT, Shih YR, Kuo TK, et al. Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells. *Stem Cells.* 2008; 26: 960-968.
36. Beasley J. Osteoarthritis and rheumatoid arthritis conservative therapeutic management. *J Hand Ther.* 2012; 25: 163-171.
37. Clayton SA, MacDonald L, Kurowska Stolarska M, et al. Mitochondria as Key Players in the Pathogenesis and Treatment of Rheumatoid Arthritis. *Front Immunol.* 2021; 12: 673916.
38. Blanco FJ, Rego I, Ruiz-Romero C. The role of mitochondria in osteoarthritis. *Nat Rev Rheumatol.* 2011; 7: 161-169.
39. Hu D, Liu Z, Qi X. Mitochondrial Quality Control Strategies Potential Therapeutic Targets for Neurodegenerative Diseases. *Front Neurosci.* 2021; 15: 746873.
40. Jeena MT, Kim S, Jin S, et al. Recent Progress in Mitochondria Targeted Drug and Drug-Free Agents for Cancer Therapy. *Cancers.* 2019; 12: 4.
41. Jiang S, Tian G, Li X, et al. Research Progress on Stem Cell Therapies for Articular Cartilage Regeneration. *Stem Cells Int.* 2021; 2021: 8882505.
42. Bartell LR, Fortier LA, Bonassar LJ, et al. Mitoprotective therapy prevents rapid strain dependent mitochondrial dysfunction after articular cartilage injury. *J Orthop Res.* 2020; 38: 1257-1267.
43. Goetz JE, Coleman MC, Fredericks DC, et al. Time dependent loss of mitochondrial function precedes progressive histologic cartilage degeneration in a rabbit meniscal destabilization model. *J Orthop Res.* 2017; 35: 590-599.
44. Koike M, Nojiri H, Ozawa Y, et al. Mechanical overloading causes mitochondrial superoxide and SOD2 imbalance in chondrocytes resulting in cartilage degeneration. *Sci Rep.* 2015; 5: 11722.
45. He Y, Wu Z, Xu L, et al. The role of SIRT3 mediated mitochondrial homeostasis in osteoarthritis. *Cell Mol Life Sci.* 2020; 77: 3729-3743.
46. Chang MC, Hung SC, Chen WY, et al. Accumulation of mitochondrial DNA with 4977 bp deletion in knee cartilage an association with idiopathic osteoarthritis. *Osteoarthritis Cartilage.* 2005; 13: 1004-1011.
47. Szafranski JD, Grodzinsky AJ, Burger E, et al. Chondrocyte mechanotransduction effects of compression on deformation of intracellular organelles and relevance to cellular biosynthesis. *Osteoarthritis Cartilage.* 2004; 12: 937-946.
48. Borrelli J Jr, Ricci WM. Acute effects of cartilage impact. *Clin Orthop Relat Res.* 2004; 423: 33-39.
49. Deng C, Zhang Q, He P, et al. Targeted apoptosis of macrophages and osteoclasts in arthritic joints is effective against advanced inflammatory arthritis. *Nat Commun.* 2021; 12: 2174.
50. Nalapko Y, Klokol D, Lakey JRT, et al. Novel Bioregenerative Options for Chondrocyte Restoration in Osteoarthritis. *Stem Cells Regen Med.* 2022; 6: 1-8.